Globalpharma Signs 7 Strategic MoUs Advancing R&D, Manufacturing and Sustainability

Globalpharma, a wholly owned subsidiary of Dubai Investments and one of the UAE’s leading pharmaceutical manufacturers, has signed seven strategic Memorandums of Understanding (MoUs) with leading partners to strengthen its capabilities across research and development, manufacturing optimisation, financing and sustainable operations.

The collaborations are structured across three strategic clusters — innovation and product development, manufacturing, efficiency and sustainability, market access, financing and expansion — supporting Globalpharma’s efforts to strengthen capabilities across the pharmaceutical value chain.

The MoUs establish collaboration frameworks with partners aligned to these clusters, including ZIM Laboratories FZE and Molkem Chemicals Pvt. Ltd. under innovation and product development; Masibus (A Sonepar company) & Rockwell Automation and 386 Sky Solar Energy Systems LLC under manufacturing, efficiency and sustainability; and Emirates Development Bank (EDB), Mubadala Bio’s Al Ittihad Drug Store (IDS) and the Emirates Drug Establishment (EDE) under market access, financing and expansion.

Commenting on the signings, Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma, said: “Strengthening the pharmaceutical sector requires a coordinated approach across innovation, manufacturing and ecosystem development. These MoUs reflect a structured effort to enhance local capabilities, enable technology and knowledge transfer and support the development of a more resilient and competitive pharmaceutical manufacturing base in the UAE. Through Globalpharma, Dubai Investments continues to support initiatives that align with national priorities while creating long-term value across the healthcare sector.”

Dr. Basem Albarahmeh, Chief Executive Officer of Globalpharma, added: “Globalpharma’s focus is on translating these partnerships into tangible operational outcomes. Through our collaboration with ZIM Laboratories, we are strengthening our product development pipeline and building advanced R&D capabilities for differentiated formulations. In parallel, our engagement with Emirates Development Bank supports access to structured financing solutions that enable scale and long-term capacity expansion. At the operational level, our partnerships with Masibus and Rockwell Automation are driving the adoption of advanced automation and digital technologies to improve throughput, quality and real-time visibility across our manufacturing facilities. At the same time, our clean energy initiative with 386 Sky Solar allows us to integrate sustainability into our operations in a measurable way, improving efficiency and reducing environmental impact. These collaborations, alongside our localisation, regulatory and distribution partnerships, strengthen our ability to deliver consistent, high-quality output while supporting long-term operational resilience.”

The collaboration with the Emirates Drug Establishment (EDE) supports pharmaceutical localisation initiatives, regulatory alignment and national medicine security, reinforcing efforts to strengthen local manufacturing capabilities and supply resilience in the UAE. Globalpharma’s partnerships with Molkem Chemicals and Mubadala Bio’s Al Ittihad Drug Store (IDS) strengthen localisation and distribution capabilities, particularly in critical therapeutic areas, while enhancing supply chain efficiency across the UAE.

The sustainability collaboration will also see the deployment of a 612 kWp rooftop sSolar photovoltaic (PV) plant at its Dubai Investment Park facility, expected to generate approximately 25.3 GWh of clean energy, avoid 11,400 tonnes of CO₂ emissions and deliver a carbon benefit equivalent to planting over 21,700 trees.

Collectively, the MoUs reinforce Globalpharma’s commitment to advancing an integrated pharmaceutical ecosystem, supporting the continued development of the UAE healthcare sector.